Latest News & Features
Big Pharma
Generics companies have often inveighed against the “arbitrary and capricious” rule | Judicial immunity granted to Vidal’s decisions at odds with Congress and SCOTUS precedent, say generics and big tech. 9 January 2024
Big Pharma
Dispute hinges on clauses set out in decade-old settlement and licensing agreement | Federal Circuit unpersuaded by arguments suggesting that a federal court erred in denying a preliminary injunction. 4 January 2024
Americas
California-based drugmaker lost Hatch-Waxman Act case after judge ruled it had failed to show patent infringement | Corcept CEO ‘confident’ decision will be reversed on appeal. 4 January 2024
Big Pharma
District judge ruled in favour of Regeneron confirming patent infringement by Mylan | Court recognised Mylan's success in challenging the validity of certain patents | Ruling happened while Regeneron filed a separate case against another competitor alleging the infringement of 51 patents. 2 January 2024
Big Pharma
Life science attorneys should see some notable developments relating to artificial intelligence, patent eligibility and the Fintiv rule, write Manita Rawat and Alexander Stein of Morgan Lewis. 2 January 2024
article
Managing partner oversees a varied range of global patent portfolios, often acting as the ‘in-house’ attorney for multinational clients. 2 January 2024
Biotechnology
Mark Hatch-Miller, who led the trial team at Susman for Globus, tells Sarah Speight how this spinal implant patent dispute, brought by a Johns Hopkins neurosurgeon, was a “heavy lift”. 21 December 2023
Big Pharma
CureVac suffers a blow following a favourable earlier opinion delivered by the German Federal Patent Court | Decision invalidates a patent related to mRNA tech. 21 December 2023
Biotechnology
Medical device company wins eight-day jury trial in spinal implant patent dispute | Johns Hopkins neurosurgeon claimed Globus Medical directly infringed multiple patents in US | Susman Godfrey | Fish & Richardson. 19 December 2023
Big Pharma
The Biden administration’s proposals target price gouging triggers resistance | The move, which includes the consideration of march-in rights for taxpayer-funded drugs, may ‘jeopardise collaborative partnerships and hinder innovation. 19 December 2023